Key facts
- Nanotein Technologies’s last known valuation is $30.0M (Aug 2023).
- It has raised $10.2M; the latest was Later Stage VC ($3.0M) in Aug 2025.
- Notable investors include Polaris Group (Drug Discovery), Sartorius Stedim Biotech.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Nanotein Technologies
- ·The full record, as it builds
Funding rounds
No funding rounds for Nanotein Technologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nanotein Technologies
Developer of ex vivo cell therapy technology designed for the expansion of T cells to support cancer treatment development. The company features engineered protein nanoparticles capable of conjugating multiple antibodies or cytokines, enhancing the quality and longevity of T cells, enabling research institutions and medical developers to advance cell therapy efficacy.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2019
- Employees
- 4
- Website
- nanoteintech.com/
- Ownership
- Privately Held (backing)
Nanotein Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nanotein Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nanotein Technologies in its N-PORT filings yet. We sweep new filings monthly.